Novogene Co., Ltd. (688315)

Overview

Novogene Co., Ltd., founded in 2011 and based in Beijing, China, operates on a global scale to offer comprehensive genomic services and solutions. With its cutting-edge technologies and expertise, Novogene caters to the increasing demand for genomic analysis across various fields, including human genetics, oncology, agriculture, and microbiology. The company's commitment to advancing genomic science has established it as a crucial player in the international genomics industry, providing insights that facilitate research, disease understanding, and the development of new therapies.

Products and Services

• Human Genome Sequencing: Delivers advanced sequencing services for human DNA, facilitating research in genetics, personalized medicine, and disease susceptibility.
• Gene Regulation: Offers solutions to explore and understand the regulation of gene expression, critical for studies in development, disease progression, and therapeutic interventions.
• Single Cell Sequencing: Provides detailed analysis at the single-cell level, allowing insights into cellular functions, heterogeneity, and interactions in complex tissues.
• Animal and Plant Solutions: Customized genomic services catering to the specific needs of animal and plant research, supporting genetic improvements, conservation, and biodiversity studies.
• Microbial Genome Sequencing: Offers comprehensive services for analyzing microbial genomes, essential for understanding microbial diversity, evolution, and pathogenesis.
• Cancer Genomic Profiling: Utilizes cutting-edge sequencing technologies for cancer research, enabling the identification of genetic mutations and alterations involved in cancer development.
• Whole Exome Sequencing: Focuses on sequencing the coding regions of the genome, instrumental in identifying genetic variants underlying various conditions.
• FFPE RNA Sequencing: Specialized in extracting and sequencing RNA from formalin-fixed paraffin-embedded samples, important for studying gene expression in archived biological materials.
• Clinical-Grade Whole Exome Sequencing Services: Provides high-accuracy exome sequencing for clinical diagnostics and research, adhering to rigorous standards for medical and clinical applications.
• NovoFocus CR: A gene coverage service tailored for hereditary cancer screening, equipped to unveil genetic predispositions to different types of cancer.
• NovoNeoantigen: A bioinformatics pipeline designed for the precise identification of cancer neoantigens, combining data from whole exome sequencing and whole transcriptome sequencing of paired tumor-normal samples to inform personalized cancer therapies.